Table 1.
Baseline characteristics of the 660 patients included in the intention to treat analysis
| Characteristic | OAC-P (n=161) | OAC-O (n=173) | O-O (n=155) | P-P (n=171) |
| Age (y) (mean (SD)) | 54 (14) | 55 (14) | 55 (13) | 55 (14) |
| Female sex (%) | 62 | 64 | 59 | 62 |
| Weight (kg) (mean (SD)) | 75 (14) | 76 (15) | 77 (14) | 76 (13) |
| Smokers (%) | 15 | 10 | 18 | 18 |
| Disease requiring NSAIDs (%) | ||||
| Systemic inflammatory diseases | 24 | 24 | 27 | 22 |
| Non-inflammatory diseases | 73 | 73 | 71 | 74 |
| Other diseases | 4 | 3 | 2 | 4 |
| Mild dyspepsia at study entry (%) | 44 | 42 | 43 | 41 |
| Lanza score “0“ at study entry (%) | ||||
| Stomach | 70 | 72 | 63 | 68 |
| Duodenum | 89 | 90 | 87 | 88 |
OAC-P, one week treatment with omeprazole, amoxicillin, and clarithromycin, followed by four weeks of placebo; OAC-O, one week treatment with omeprazole, amoxicillin, and clarithromycin, followed by four weeks of omeprazole; O-O, five week treatment with omeprazole; P-P, five week treatment with placebo.